PRINCETON, NJ – May 15, 2017 – Certara today announced that it has appointed Sandy Allerheiligen, PhD, to the newly-created role of Senior Vice President of Health Economics and Education.
PRINCETON, NJ – Apr. 19, 2017 – Certara today announced the launch of a new solution for preparing, analyzing and submitting PK data in Clinical Data Exchange Standards Consortium (CDISC) format. CDISC supports the acquisition, exchange, submission and archiving of non-clinical and clinical data.
PRINCETON, NJ – Apr. 5. 2017 – Certara today announced that its d3 Medicine company has been selected to conduct a national audit of Australia’s medical countermeasures (MCM) product research and development (R&D) capabilities and capacity.
PRINCETON, NJ – Mar. 13, 2017 – Certara today announced that its scientists will be highlighting pharmacokinetic (PK) and pharmacodynamic (PD) modeling advances during 19 sessions at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2017 Annual Meeting.
PRINCETON, NJ – Mar. 9, 2017 – Certara today announced the launch of Simcyp Access, a new cloud-based licensing approach that provides trained individuals at smaller pharmaceutical companies (less than 500 employees) with a method for using Certara’s Simcyp Population-based Simulator in research projects.
PRINCETON, NJ – Feb. 22, 2017 – Certara today announced that the Standards Council of Canada (SCC) has awarded Good Laboratory Practices (GLP) certification to its Certara Strategic Consulting (CSC) Montreal facility.
PRINCETON, NJ – Feb. 15, 2017 – Certara today announced that Professor Piet van der Graaf, PharmD, PhD, its vice president of quantitative systems pharmacology, has been appointed a F1000Prime faculty member.
PRINCETON, NJ – Jan. 31, 2017 – Certara today announced that it has released D360 version 9.0 along with D360 Express, its data informatics platform for discovery scientists. D360 is a self-service data access, integration and visualization solution.
PRINCETON, NJ – Jan. 25, 2017 – Certara today announced that it is launching a Quantitative Systems Pharmacology (QSP) Immunogenicity Consortium. Modeled after Certara’s highly successful Simcyp Consortium, the QSP Immunogenicity Consortium brings together leading biopharmaceutical companies in a pre-competitive environment to cooperatively develop an Immunogenicity Simulator.
PRINCETON, NJ – Jan. 10, 2017 – Certara today announced that it has released version 16 of its Simcyp Population-based Simulator. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated platform for determining first-in-human dose selection, designing more efficient and effective clinical studies, evaluating new drug formulations, and predicting drug-drug interactions (DDIs) and pharmacokinetic (PK) outcomes in clinical populations.